Determination of output factors for small proton therapy fields.

Current protocols for the measurement of proton dose focus on measurements under reference conditions; methods for measuring dose under patient-specific conditions have not been standardized. In particular, it is unclear whether dose in patient-specific fields can be determined more reliably with or without the presence of the patient-specific range compensator. The aim of this study was to quantitatively assess the reliability of two methods for measuring dose per monitor unit (DIMU) values for small-field treatment portals: one with the range compensator and one without the range compensator. A Monte Carlo model of the Proton Therapy Center-Houston double-scattering nozzle was created, and estimates of D/MU values were obtained from 14 simulated treatments of a simple geometric patient model. Field-specific D/MU calibration measurements were simulated with a dosimeter in a water phantom with and without the range compensator. D/MU values from the simulated calibration measurements were compared with D/MU values from the corresponding treatment simulation in the patient model. To evaluate the reliability of the calibration measurements, six metrics and four figures of merit were defined to characterize accuracy, uncertainty, the standard deviations of accuracy and uncertainty, worst agreement, and maximum uncertainty. Measuring D/MU without the range compensator provided superior results for five of the six metrics and for all four figures of merit. The two techniques yielded different results primarily because of high-dose gradient regions introduced into the water phantom when the range compensator was present. Estimated uncertainties (approximately 1 mm) in the position of the dosimeter in these regions resulted in large uncertainties and high variability in D/MU values. When the range compensator was absent, these gradients were minimized and D/MU values were less sensitive to dosimeter positioning errors. We conclude that measuring D/MU without the range compensator present provides more reliable results than measuring it with the range compensator in place.

[1]  Hanne M Kooy,et al.  Target volume dose considerations in proton beam treatment planning for lung tumors. , 2005, Medical physics.

[2]  M. Wagner.  Automated range compensation for proton therapy. , 1982, Medical physics.

[3]  M Goitein,et al.  Compensating for heterogeneities in proton radiation therapy. , 1984, Physics in medicine and biology.

[4]  D. Bonnett,et al.  Code of practice for clinical proton dosimetry. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Harald Paganetti,et al.  The prediction of output factors for spread-out proton Bragg peak fields in clinical practice , 2005, Physics in medicine and biology.

[6]  L. Verhey,et al.  Protocol for Heavy Charged-Particle Therapy Beam Dosimetry , 1986 .

[7]  Design tools for proton therapy nozzles based on the double-scattering foil technique. , 2005, Radiation protection dosimetry.

[8]  A. Kacperek.  Clinical Proton Dosimetry Part I: Beam Production, Beam Delivery and Measurement of Absorbed Dose (ICRU Report 59) , 2000 .

[9]  Thomas Bortfeld,et al.  Monitor unit calculations for range-modulated spread-out Bragg peak fields. , 2003, Physics in medicine and biology.

[10]  P Chauvel,et al.  Monte Carlo simulation of a protontherapy platform devoted to ocular melanoma. , 2005, Medical physics.

[11]  Daniel W. Miller,et al.  Methodologies and tools for proton beam design for lung tumors. , 2001, International journal of radiation oncology, biology, physics.

[12]  M. Goitein.  Compensation for inhomogeneities in charged particle radiotherapy using computed tomography. , 1978, International journal of radiation oncology, biology, physics.

[13]  W. Newhauser,et al.  Dosimetry for ocular proton beam therapy at the Harvard Cyclotron Laboratory based on the ICRU Report 59. , 2002, Medical physics.

[14]  W. Sweet,et al.  The Bragg peak of a proton beam in intracranial therapy of tumors. , 1962, Transactions of the American Neurological Association.

[15]  R. Wilson.  Radiological use of fast protons. , 1946, Radiology.

[16]  W. Newhauser,et al.  Calculations of neutron dose equivalent exposures from range-modulated proton therapy beams , 2005, Physics in medicine and biology.

[17]  Reinhard W. Schulte,et al.  Conformal proton therapy for prostate carcinoma. , 1998, International journal of radiation oncology, biology, physics.

[18]  Proton beam dosimetry for radiosurgery: implementation of the ICRU Report 59 at the Harvard Cyclotron Laboratory. , 2002, Physics in medicine and biology.

[19]  L. Verhey,et al.  Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.

[20]  E. Gragoudas,et al.  Uveal melanoma: proton beam irradiation. , 2005, Ophthalmology clinics of North America.